Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
Through this collaboration, the erstwhile Government Maternity Hospital in Kanakapura Taluk has been rebuilt and the new hospital has facilities including oxygen and medical gas pipelines
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
The new project further expands the partner's long-term collaboration on new technologies for R&D
This partnership stemmed from a successful customer-supplier relationship spanning several years.
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Subscribe To Our Newsletter & Stay Updated
